查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1993112

犬用疫苗市场：2026年至2032年全球市场预测（依疫苗类型、科技、动物年龄层、通路和最终用户划分）

Dog Vaccines Market by Vaccine Type, Technology, Animal Age Group, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，犬用疫苗市场价值将达到 24 亿美元，到 2026 年将成长至 26 亿美元，到 2032 年将达到 41.8 亿美元，复合年增长率为 8.26%。

主要市场统计数据
基准年 2025 24亿美元
预计年份：2026年 26亿美元
预测年份：2032年 41.8亿美元
复合年增长率 (%) 8.26%

简要概述现代犬用疫苗领域，将科学创新与商业性现实和营运影响联繫起来。

科学进步、宠物饲主不断变化的期望以及监管趋势正在推动犬类健康管理领域的持续发展。本执行摘要在于犬用疫苗领域，概述了影响相关人员决策的关键驱动因素、新兴方法和商业性趋势。其目的是帮助企业主管、临床医生和产品负责人了解影响疫苗研发、分销和应用的结构性动态，并为营运管理和投资优先排序提供实用见解。

技术进步、兽医保健模式的变革以及更严格的监管，都在促成犬用疫苗。

近年来，多项变革性变化重塑了犬用疫苗的研发、评估和交付，为价值链上的所有相关人员带来了机会和挑战。分子平台技术的进步开闢了新的治疗途径，而低温运输物流和数位医疗领域的同步发展则改变了分销模式，并为宠物饲主和兽医专业人员的互动创造了新的途径。这些变化也反映了人们期望的更广泛转变。宠物饲主越来越倾向于将伴侣动物的健康观点“人类级别的护理”，从而推动了对更高安全性和更透明的疗效数据的需求。

评估 2025 年美国关税措施对供应链韧性、采购决策和下游采购经济的策略影响。

美国贸易政策趋势和关税调整为采购计划、跨境伙伴关係以及关键投入品的供应带来了新的变数。关税变化不仅影响成品疫苗的运输，也影响上游原料、试剂和生产所需专用设备的流动。由于关税会改变接收成本并促使企业将某些生产活动在奖励，各组织正在重新审视筹资策略，并评估建立区域生产基地的可行性，以降低贸易波动带来的风险。

可操作的细分讯息，将疫苗类型、分销渠道趋势、最终用户偏好、技术平台和动物年龄组进行匹配，以指导优先战略选择。

精准的市场区隔对于优化疫苗类型、分销管道、终端用户需求、技术平台和动物年龄组的产品开发和市场进入策略至关重要。就疫苗类型而言，灭活疫苗、减毒活病毒疫苗和重组疫苗在研发和临床应用方面有显着差异，每种疫苗都有独特的安全性和储存特性，这些特性会影响临床应用和传播策略。在分销方面，分销管道涵盖医疗机构和零售管道，其中兽医院、线上零售商、药局和兽医诊所等都以其独特的方式影响临床趋势、库存模式和客户体验。

从综合考虑美洲、欧洲、中东、非洲和亚太地区的监管多样性、分销管道能力和文化态度出发，建构全面的区域观点。

区域趋势在塑造犬用疫苗的监管时间表、分销基础设施和竞争格局方面发挥着至关重要的作用，这体现在各个主要区域独特的商业环境中。在美洲，对伴侣动物医疗保健的高度重视，加上成熟的兽医网络和私营部门对新平台的大力投资，使得新配方在获得监管核准和报销机制后能够迅速得到推广。而欧洲、中东和非洲则呈现更为复杂的生态系统，监管协调程度不一，兽医诊所密度和购买力也有差异。考虑到所有这些因素，必须制定符合当地合规性和流通结构的市场准入和市场拓展策略。

对犬用疫苗领域进行策略竞争格局分析，阐述现有公司的优势、生物技术创新和製造伙伴关係关係如何融合，从而创造差异化的竞争优势。

犬用疫苗领域的竞争动态受到多种因素的影响，包括成熟的兽用生物製品公司、创新生物技术参与企业以及支持专业平台规模化生产的契约製造（CMO）。成熟公司在分销网络、兽医信任度和监管合规经验方面保持优势，而新参与企业通常具备平台灵活性和差异化策略，能够快速适应新的靶点，例如mRNA和基于载体的构建体。伙伴关係与授权协议是将商业性覆盖范围与技术新颖性相结合的常用机制，而与合约开发和生产组织（CDMO）建立策略联盟对于那些希望在不大幅增加固定资产资本投入的情况下加快产品上市速度的公司至关重要。

为确保可持续的竞争优势，为高阶主管提供可操作的、优先考虑的策略建议，以协调创新、供应链韧性、相关人员参与和分销执行。

动物用药品领域的领导者应务实地将创新投资、供应链强化和相关人员参与相结合，以管控风险并抓住机会。优先考虑能够满足临床未满足需求且具备可扩展生产能力的平台技术。这意味着评估DNA、mRNA和载体方法时，不仅要考虑其免疫学潜力，还要考虑其可生产性、低温运输影响和监管核准管道。同时，制定灵活的筹资策略，确保关键试剂的多元化来源，并探索区域生产方案，以降低关税和运输中断带来的风险。

采用严谨的混合方法研究方法，结合关键相关人员的访谈、二手技术文献和情境分析，以检验策略见解。

本研究采用混合方法，整合质性和量性讯息，强调三角验证和具体检验。主要资讯来源包括对兽医、实验室技术人员、采购负责人和行业高管的结构化访谈，以及针对相关人员的研讨会，旨在识别该领域的营运限制和应用驱动因素。次要资讯来源包括监管指导文件、同行评审文献、临床实验室报告和专利揭露，目的是确保技术准确性，并将技术趋势置于科学规范的框架内。

整合策略挑战和实际考量因素，指导各组织在市场上稳健、以证据为基础部署犬用疫苗。

总之，犬用疫苗领域处于科学创新、不断演变的分销模式以及复杂的监管和贸易环境的交汇点。能够成功驾驭这一领域的相关人员，需要具备以下能力：将平台技术进步转化为具有临床意义的产品；调整分销和宣传活动以满足终端用户的期望；以及设计能够抵御政策和物流干扰的供应链。战略挑战在于如何将技术雄心与实际可行性结合，以确保新技术能够安全可靠地惠及动物及其饲主，并建立长期的信任。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 工业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：犬用疫苗市场：依疫苗类型划分

  • 灭活疫苗
  • 减毒疫苗
  • 重组疫苗

第九章：犬用疫苗市场：依技术划分

  • DNA
  • mRNA
    • 非复製型
    • 自放大
  • 向量

第十章：犬用疫苗市场：依动物年龄组别划分

  • 成犬
  • 小狗
  • 老年犬

第十一章：犬用疫苗市场：依通路划分

  • 动物医院
  • 线上零售
  • 药局
  • 动物诊所

第十二章：犬用疫苗市场：依最终用户划分

  • 宠物饲主
  • 研究机构
  • 动物医院

第十三章：犬用疫苗市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章：犬用疫苗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章：犬用疫苗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国犬用疫苗市场

第十七章：中国犬用疫苗市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Anicon Labor GmbH by SNA group
  • Biogenesis Bago SA
  • Boehringer Ingelheim International GmbH
  • Brilliant Bio Pharma Private limited
  • Ceva Sante Animale
  • China Animal Husbandry Industry Co., Ltd.
  • Elanco LLC
  • Endovac Animal Health, LLC
  • Heska Corporation
  • Hester Biosciences Limited
  • HIPRA, SA
  • Indian Immunologicals Limited
  • Merck KGaA
  • Neogen Corporation
  • Phibro Animal Health Corporation
  • Sanofi SA
  • Torigen Pharmaceuticals Inc.
  • Vaxxinova GmbH
  • VEROVACCiNES GmbH
  • Vetoquinol SA
  • Virbac, Inc.
  • Zoetis Inc.
Product Code: MRR-1A1A064C028B

The Dog Vaccines Market was valued at USD 2.40 billion in 2025 and is projected to grow to USD 2.60 billion in 2026, with a CAGR of 8.26%, reaching USD 4.18 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.40 billion
Estimated Year [2026] USD 2.60 billion
Forecast Year [2032] USD 4.18 billion
CAGR (%) 8.26%

A concise orientation to the contemporary canine vaccine environment that maps scientific innovation to commercial realities and operational implications

The landscape of canine health management is undergoing sustained evolution as scientific advances, shifting pet owner expectations, and regulatory developments converge. This executive summary introduces a focused exploration of the dog vaccines domain, outlining critical drivers, emergent modalities, and the commercial contours that influence stakeholder decision-making. The objective is to orient executives, clinicians, and product strategists to the structural dynamics shaping vaccine development, distribution, and adoption while highlighting the practical implications for operations and investment prioritization.

Across veterinary practice and companion animal care, vaccination remains a cornerstone of preventive medicine. Nonetheless, recent years have seen a widening array of vaccine technologies, diversified delivery pathways, and more sophisticated demand signals from pet owners who increasingly value safety, convenience, and evidence of efficacy. This introduction frames subsequent sections by underscoring the interplay between scientific innovation and market-facing execution, setting expectations for how strategic choices will affect organizational competitiveness and animal welfare outcomes.

Moving forward, the assessment emphasizes translation of scientific capability into accessible products, the influence of channel economics on uptake, and the role of regulatory clarity in enabling novel modalities. In doing so, it prepares readers to interpret segmentation-level insights, regional variances, and the implications of trade policy on planning horizons and procurement strategies.

How converging technological advances, shifting veterinary care models, and regulatory tightening are driving a structural transformation across canine vaccine development and delivery

Recent years have seen several transformative shifts that are reshaping how vaccines for dogs are developed, vetted, and delivered, creating both opportunities and constraints for stakeholders across the value chain. Advances in molecular platforms have opened new therapeutic pathways, while parallel progress in cold-chain logistics and digital health has altered distribution models and created room for novel engagement with pet owners and veterinary professionals. These shifts also reflect broader changes in expectations: pet owners increasingly view companion animal health through a lens of human-grade care, driving demand for higher safety profiles and more transparent efficacy data.

At the same time, regulatory agencies have become more proactive in articulating requirements for newer modalities, leading to clearer pathways for DNA, mRNA, and vector-based candidates but also imposing stringent demonstration of long-term safety. The proliferation of online retail and telehealth-enabled veterinary services has disrupted traditional distribution norms and forced incumbents to adapt service models and client communications. Furthermore, integration of genomic surveillance and pathogen mapping into routine practice is enabling more targeted vaccine design, shortening the loop between outbreak detection and product iteration.

Consequently, innovators and established manufacturers must balance accelerated R&D trajectories with rigorous evidence generation and supply chain resilience. As a result, strategic imperatives now include investment in platform interoperability, enhanced stakeholder education, and adaptive manufacturing capacity that can respond to both routine immunization schedules and emerging pathogen threats.

Assessing the strategic consequences of United States tariff measures in 2025 on supply chain resilience, sourcing decisions, and downstream procurement economics

Trade policy developments and tariff adjustments enacted by the United States have introduced new variables into planning for procurement, cross-border partnerships, and the supply of critical inputs. Tariff changes affect not only finished vaccine shipments but also the upstream flow of raw materials, reagents, and specialized equipment that are essential to production. As tariffs alter landed costs and create incentives to localize specific manufacturing activities, organizations are reassessing sourcing strategies and evaluating the feasibility of regional production hubs to mitigate exposure to trade volatility.

These shifts have also prompted companies to reexamine contractual frameworks with suppliers and distributors, placing greater emphasis on flexibility clauses and dual-sourcing arrangements. In parallel, licensors and contract manufacturers are exploring alternative commercial models that can cushion the impact of tariff-induced cost fluctuations, including long-term supply agreements and onshore capacity investments. For stakeholders engaged in clinical development, changes in import duties affecting laboratory reagents and animal health diagnostics are being monitored closely, since procurement timelines may be lengthened when sourcing corridors become less predictable.

Ultimately, the cumulative impact of tariff measures in 2025 is encouraging a strategic pivot toward resilient supply chain design, stronger supplier relationships, and greater transparency into total landed costs. Executives should consider tariff exposure as one component of a broader risk management framework that includes regulatory, operational, and reputational factors.

Actionable segmentation intelligence that aligns vaccine type, channel dynamics, end-user preferences, technological platforms, and animal age cohorts to inform prioritized strategic choices

A nuanced understanding of segmentation is essential for tailoring product development and go-to-market strategies across vaccine modality, distribution pathways, end-user needs, technological platforms, and animal age cohorts. When considering vaccine type, there is a clear differentiation in development and clinical profiling between inactivated preparations, live attenuated formulations, and recombinant constructs, each presenting unique safety and storage characteristics that influence clinical adoption and communication strategies. Transitioning to distribution considerations, channels span institutional settings and consumer-facing outlets, with Animal Hospitals, Online Retail, Pharmacies, and Veterinary Clinics each shaping point-of-care dynamics, stocking patterns, and customer experience in distinct ways.

End-user segmentation reveals divergent decision criteria: Pet Owners prioritize convenience, perceived safety, and value communication; Research Institutes focus on assay compatibility and reproducibility for experimental work; Veterinary Hospitals require proven efficacy, ease of administration, and reliable supply. Technological segmentation is particularly consequential as DNA, mRNA, and Vector platforms demonstrate different timelines for regulatory validation, manufacturing scaling, and cold-chain dependencies; within mRNA there is further technical distinction between Non-Replicating and Self-Amplifying formats, which carries implications for dosing, immunogenicity, and production throughput. Age-based segmentation underscores clinical differentiation across Adult, Puppy, and Senior cohorts, given that immune competency, dosing schedules, and comorbidity profiles vary with age and thereby impact safety monitoring and communication strategies.

Integrated segmentation analysis indicates that winning strategies will align product profiles with channel economics and end-user expectations while leveraging platform advantages selectively for age cohorts that realize the greatest clinical benefit. Accordingly, cross-functional planning teams should map segmentation intersections to prioritize clinical programs, distribution investments, and educational outreach that resonate with each stakeholder cluster.

Comprehensive regional vantage points that reconcile regulatory diversity, channel capacity, and cultural attitudes across the Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics play a fundamental role in shaping regulatory timelines, distribution infrastructure, and the competitive landscape for canine vaccines, with distinct operating contexts across major geographies. In the Americas, a strong emphasis on companion animal health services is paired with well-established veterinary networks and robust private-sector investment in novel platforms, which fosters rapid uptake of new formulations when regulatory clearance and reimbursement-like mechanisms align. Conversely, Europe, Middle East & Africa presents a more heterogeneous ecosystem characterized by variable regulatory harmonization, differences in veterinary practice density, and diverse purchasing power, all of which necessitate tailored launch and access strategies that account for localized compliance and channel structures.

Asia-Pacific exhibits a mix of high-volume markets with rapidly modernizing veterinary infrastructure and emerging regions where access constraints and differing clinical priorities shape demand. Across all regions, cold-chain logistics, import regulations, and local manufacturing capacity influence placement decisions and partnership models. Moreover, cultural attitudes toward pet ownership, preventive care awareness, and the role of veterinarians in guiding vaccination choices introduce behavioral nuances that companies must address through locally adapted education and outreach programs.

Taken together, regional planning should emphasize regulatory due diligence, partnership selection that leverages local channel strengths, and investment in distribution capabilities that reflect the operational realities of each geography. This regional sensitivity will enable more effective product rollouts and greater alignment with clinician and pet owner expectations.

Strategic competitive landscape analysis showing how incumbent strengths, biotech innovation, and manufacturing partnerships converge to create differentiated advantage in the canine vaccine sector

Competitive dynamics in the dog vaccine sector are being influenced by a mix of established veterinary biologics firms, innovative biotechnology entrants, and contract manufacturers that support specialized platform scale-up. Incumbents retain advantages in distribution networks, practitioner trust, and regulatory experience, while newer entrants often bring platform agility and differentiated approaches such as mRNA or vector-based constructs that can be adapted rapidly to emerging targets. Partnerships and licensing deals are common mechanisms to combine commercial reach with technical novelty, and strategic alliances with contract development and manufacturing organizations are critical for firms seeking to accelerate time-to-market without overextending capital investment in fixed assets.

In addition, increasing emphasis on data-driven safety monitoring and post-marketing evidence collection is favoring competitors that can integrate digital tools and real-world data capture into their product propositions. Companies that invest in robust pharmacovigilance frameworks and clinician education programs are more likely to build long-term trust with veterinary professionals and pet owners. Meanwhile, supply chain reliability and the ability to manage cold-chain-sensitive products at scale remain differentiators that affect commercial sustainability. Consequently, market leaders will be those that combine technological innovation with operational excellence and a disciplined approach to regulatory engagement and stakeholder communication.

Practical and prioritized strategic recommendations for executives to align innovation, supply chain resilience, stakeholder engagement, and distribution execution for sustained advantage

Leaders in the animal health arena should pursue a pragmatic blend of innovation investment, supply chain fortification, and stakeholder engagement to capture opportunity while managing risk. First, prioritize platform technologies that align with clinical unmet needs and can be supported by scalable manufacturing; this means evaluating DNA, mRNA, and vector approaches not only for their immunological potential but for manufacturability, cold-chain implications, and regulatory pathways. Concurrently, develop flexible sourcing strategies that include dual suppliers for critical reagents and consider regional production options to reduce exposure to tariff and shipping disruptions.

Second, invest in clinician and owner education to foster confidence in newer modalities and to clarify administration schedules across life stages from puppy through senior animals. Third, enhance pharmacovigilance and real-world evidence programs to accelerate acceptance and to inform iterative product improvement. Fourth, design distribution strategies that reflect channel-specific behaviors, ensuring that Animal Hospitals, Online Retail, Pharmacies, and Veterinary Clinics each receive tailored product presentation, training, and logistical support. Finally, cultivate strategic partnerships with research institutions and contract manufacturers to balance in-house capability with external expertise and capacity, enabling rapid responses to pathogen emergence while maintaining operational discipline.

A rigorous mixed-methods research approach that integrates primary stakeholder interviews, secondary technical literature, and scenario analysis to validate strategic insights

This research synthesizes qualitative and quantitative inputs through a mixed-methods approach that emphasizes triangulation and subject-matter validation. Primary inputs include structured interviews with veterinary clinicians, laboratory scientists, procurement professionals, and industry executives, complemented by targeted stakeholder workshops that surfaced on-the-ground operational constraints and adoption drivers. Secondary sources encompass regulatory guidance documents, peer-reviewed literature, clinical trial reports, and patent disclosures to ensure technical accuracy and to situate technological trends within the scientific canon.

Analytical methods included cross-segmentation mapping to identify high-impact intersections among vaccine type, distribution channels, end-user priorities, technology platform, and animal age group. Scenario analysis was applied to evaluate supply chain and trade-policy sensitivities, while expert review panels validated assumptions and interpretation of complex technical issues. Throughout the process, care was taken to corroborate claims with multiple evidence streams and to document uncertainty explicitly, enabling readers to distinguish between well-supported insight and areas requiring further empirical work. This methodological rigor underpins the recommendations and ensures that strategic choices are grounded in a defensible evidentiary base.

A synthesis of strategic imperatives and practical considerations that guide organizations toward resilient, evidence-driven deployment of canine vaccines across markets

In closing, the dog vaccines domain sits at the intersection of scientific innovation, evolving distribution models, and complex regulatory and trade environments. Stakeholders who successfully navigate this space will be those that translate platform advances into clinically meaningful products, adapt distribution and education to meet end-user expectations, and design supply chains that withstand policy and logistical disruption. The strategic imperative is to couple technological ambition with operational pragmatism so that new modalities can reach animals and owners safely, reliably, and in a way that supports long-term trust.

Looking ahead, the organizations that win will be those that build adaptive capability across R&D, manufacturing, and commercial operations, while maintaining a relentless focus on evidence generation and stakeholder communication. By aligning segmentation-specific product design with regional realities and robust risk management, leaders can achieve durable impact in improving canine health outcomes and in creating sustainable commercial pathways for next-generation vaccines.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Dog Vaccines Market, by Vaccine Type

  • 8.1. Inactivated
  • 8.2. Live Attenuated
  • 8.3. Recombinant

9. Dog Vaccines Market, by Technology

  • 9.1. DNA
  • 9.2. mRNA
    • 9.2.1. Non-Replicating
    • 9.2.2. Self-Amplifying
  • 9.3. Vector

10. Dog Vaccines Market, by Animal Age Group

  • 10.1. Adult
  • 10.2. Puppy
  • 10.3. Senior

11. Dog Vaccines Market, by Distribution Channel

  • 11.1. Animal Hospitals
  • 11.2. Online Retail
  • 11.3. Pharmacies
  • 11.4. Veterinary Clinics

12. Dog Vaccines Market, by End User

  • 12.1. Pet Owners
  • 12.2. Research Institutes
  • 12.3. Veterinary Hospitals

13. Dog Vaccines Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Dog Vaccines Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Dog Vaccines Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Dog Vaccines Market

17. China Dog Vaccines Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Anicon Labor GmbH by SNA group
  • 18.6. Biogenesis Bago S.A.
  • 18.7. Boehringer Ingelheim International GmbH
  • 18.8. Brilliant Bio Pharma Private limited
  • 18.9. Ceva Sante Animale
  • 18.10. China Animal Husbandry Industry Co., Ltd.
  • 18.11. Elanco LLC
  • 18.12. Endovac Animal Health, LLC
  • 18.13. Heska Corporation
  • 18.14. Hester Biosciences Limited
  • 18.15. HIPRA, S.A.
  • 18.16. Indian Immunologicals Limited
  • 18.17. Merck KGaA
  • 18.18. Neogen Corporation
  • 18.19. Phibro Animal Health Corporation
  • 18.20. Sanofi S.A.
  • 18.21. Torigen Pharmaceuticals Inc.
  • 18.22. Vaxxinova GmbH
  • 18.23. VEROVACCiNES GmbH
  • 18.24. Vetoquinol SA
  • 18.25. Virbac, Inc.
  • 18.26. Zoetis Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL DOG VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DOG VACCINES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL DOG VACCINES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DOG VACCINES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL DOG VACCINES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DOG VACCINES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL DOG VACCINES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES DOG VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA DOG VACCINES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DOG VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DOG VACCINES MARKET SIZE, BY INACTIVATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DOG VACCINES MARKET SIZE, BY INACTIVATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DOG VACCINES MARKET SIZE, BY INACTIVATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DOG VACCINES MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DOG VACCINES MARKET SIZE, BY LIVE ATTENUATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DOG VACCINES MARKET SIZE, BY LIVE ATTENUATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DOG VACCINES MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DOG VACCINES MARKET SIZE, BY RECOMBINANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DOG VACCINES MARKET SIZE, BY RECOMBINANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DOG VACCINES MARKET SIZE, BY DNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DOG VACCINES MARKET SIZE, BY DNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DOG VACCINES MARKET SIZE, BY DNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DOG VACCINES MARKET SIZE, BY MRNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DOG VACCINES MARKET SIZE, BY MRNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DOG VACCINES MARKET SIZE, BY MRNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DOG VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DOG VACCINES MARKET SIZE, BY NON-REPLICATING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DOG VACCINES MARKET SIZE, BY NON-REPLICATING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DOG VACCINES MARKET SIZE, BY NON-REPLICATING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DOG VACCINES MARKET SIZE, BY SELF-AMPLIFYING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DOG VACCINES MARKET SIZE, BY SELF-AMPLIFYING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DOG VACCINES MARKET SIZE, BY SELF-AMPLIFYING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DOG VACCINES MARKET SIZE, BY VECTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DOG VACCINES MARKET SIZE, BY VECTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DOG VACCINES MARKET SIZE, BY VECTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DOG VACCINES MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DOG VACCINES MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DOG VACCINES MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DOG VACCINES MARKET SIZE, BY PUPPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DOG VACCINES MARKET SIZE, BY PUPPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DOG VACCINES MARKET SIZE, BY PUPPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DOG VACCINES MARKET SIZE, BY SENIOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DOG VACCINES MARKET SIZE, BY SENIOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL DOG VACCINES MARKET SIZE, BY SENIOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL DOG VACCINES MARKET SIZE, BY ANIMAL HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL DOG VACCINES MARKET SIZE, BY ANIMAL HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL DOG VACCINES MARKET SIZE, BY ANIMAL HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL DOG VACCINES MARKET SIZE, BY ONLINE RETAIL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL DOG VACCINES MARKET SIZE, BY ONLINE RETAIL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL DOG VACCINES MARKET SIZE, BY ONLINE RETAIL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL DOG VACCINES MARKET SIZE, BY PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL DOG VACCINES MARKET SIZE, BY PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL DOG VACCINES MARKET SIZE, BY PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL DOG VACCINES MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL DOG VACCINES MARKET SIZE, BY VETERINARY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL DOG VACCINES MARKET SIZE, BY VETERINARY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL DOG VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL DOG VACCINES MARKET SIZE, BY PET OWNERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL DOG VACCINES MARKET SIZE, BY PET OWNERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL DOG VACCINES MARKET SIZE, BY PET OWNERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL DOG VACCINES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL DOG VACCINES MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL DOG VACCINES MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL DOG VACCINES MARKET SIZE, BY VETERINARY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL DOG VACCINES MARKET SIZE, BY VETERINARY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL DOG VACCINES MARKET SIZE, BY VETERINARY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL DOG VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. AMERICAS DOG VACCINES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS DOG VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS DOG VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA DOG VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. NORTH AMERICA DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA DOG VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA DOG VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA DOG VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. LATIN AMERICA DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. LATIN AMERICA DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA DOG VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA DOG VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA DOG VACCINES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA DOG VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA DOG VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE DOG VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE DOG VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE DOG VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. MIDDLE EAST DOG VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. MIDDLE EAST DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. MIDDLE EAST DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST DOG VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 102. MIDDLE EAST DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. MIDDLE EAST DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST DOG VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. AFRICA DOG VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. AFRICA DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. AFRICA DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 108. AFRICA DOG VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 109. AFRICA DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. AFRICA DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 111. AFRICA DOG VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC DOG VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC DOG VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC DOG VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL DOG VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. ASEAN DOG VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. ASEAN DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. ASEAN DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 123. ASEAN DOG VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 124. ASEAN DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. ASEAN DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN DOG VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. GCC DOG VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GCC DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. GCC DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 130. GCC DOG VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 131. GCC DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GCC DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 133. GCC DOG VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPEAN UNION DOG VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPEAN UNION DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPEAN UNION DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPEAN UNION DOG VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPEAN UNION DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPEAN UNION DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPEAN UNION DOG VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. BRICS DOG VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. BRICS DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. BRICS DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 144. BRICS DOG VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 145. BRICS DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. BRICS DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 147. BRICS DOG VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. G7 DOG VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. G7 DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. G7 DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 151. G7 DOG VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 152. G7 DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. G7 DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 154. G7 DOG VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. NATO DOG VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. NATO DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. NATO DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 158. NATO DOG VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 159. NATO DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 160. NATO DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 161. NATO DOG VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL DOG VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. UNITED STATES DOG VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 164. UNITED STATES DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. UNITED STATES DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 166. UNITED STATES DOG VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 167. UNITED STATES DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. UNITED STATES DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 169. UNITED STATES DOG VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. CHINA DOG VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 171. CHINA DOG VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. CHINA DOG VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 173. CHINA DOG VACCINES MARKET SIZE, BY MRNA, 2018-2032 (USD MILLION)
  • TABLE 174. CHINA DOG VACCINES MARKET SIZE, BY ANIMAL AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 175. CHINA DOG VACCINES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 176. CHINA DOG VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)